Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062621 | 0.79 | MAPT (0.41) | HSD17B1MAPTHPGDRAB9ALMNA | |
| SCHEMBL2680684 | 0.79 | MAPT (0.41) | HSD17B1MAPTHPGDRAB9ALMNA | |
| SCHEMBL578580 | 0.78 | TSHR (0.52) | MAPTL3MBTL1SMN1; SMN2CA5AALDH1A1 | |
| SCHEMBL9709057 | 0.77 | MAPT (0.42) | HSD17B1MAPTHPGDRAB9ALMNA | |
| SCHEMBL1206454 | 0.77 | KMT2A (0.45) | HSD17B1MAPTHPGDRAB9ALMNA | |
| SCHEMBL1206442 | 0.77 | MAPT (0.40) | HSD17B1MAPTHPGDRAB9ALMNA | |
| SCHEMBL1303104 | 0.76 | PARP10 (0.43) | MAPTL3MBTL1KMT2ASMN1; SMN2NOS1 | |
| SCHEMBL27624234 | 0.76 | HDAC8 (0.52) | HPGDSMN1; SMN2 | |
| SCHEMBL6197887 | 0.76 | CA1 (0.57) | MAPTHPGDRAB9ALMNAL3MBTL1 | |
| SCHEMBL5672001 | 0.74 | KMT2A (0.42) | HSD17B1MAPTHPGDRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105998028-A | Hydroxylamine compounds and methods of their use | 科尔比制药公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103497148-B | Hydroxylamine compound and usage thereof | COLBY PHARMACEUTICAL COMPANY (US) | 2016-06-01 | — | — | CN | disclosed |
| CN-103497148-A | Hydroxylamine compounds and methods of their use | OTHERA HOLDING INC | 2014-01-08 | — | — | CN | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101687786-B | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2013-05-22 | — | — | CN | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| CN-101687786-A | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | GIVAUDAN SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| WO-2006076821-A1 | 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR | GIVAUDAN SA (CH) | 2006-07-27 | — | — | WO | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| CN-1152864-C | Phenylphenanthridines with PDE-IV inhibiting activity | ��̹��ҽҩ��˾ | 2004-06-09 | — | — | CN | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| CN-1336919-A | Phenylphenanthridines with PDE-IV inhibiting activity | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-02-20 | — | — | CN | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | TYR, MAL2, ACMSD | HSD17B1 1271/4885MAPT 3095/4885HPGD 1542/4885 |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | HSD17B1 176/4885MAPT 3557/4885HPGD 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.